Medical device firm Boston Scientific has secured approval from the US Food and Drug Administration (FDA) for its Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System, and magnetic resonance (MR) conditional labelling for all previously implanted Emblem S-ICD Systems.
The Emblem S-ICD Systems serve as treatment options for patients vulnerable to sudden cardiac arrest (SCA), which leaves the heart and vasculature untouched, decreasing the risk of complications associated with conventional transvenous implantable cardioverter-defibrillators.
